The Law Offices of Frank R. Cruz announces an investigation of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?

On February 25, 2026, Procept reported fourth quarter and full year 2025 results, disclosing a larger-than-expected adjusted EBITDA loss and cutting its full-year 2026 revenue guidance to a range of $390 million to $410 million (down from its prior range of $410 million to $430 million). The Company attributed lower U.S. consumable revenue in part to eliminating its historical practice of providing discounts on bulk purchases in order to better align handpiece sales with procedure volumes.

On this news, Procept’s stock price fell $4.21 per share, or 15.12%, to close at $23.63 per share on February 26, 2026, thereby injuring investors.